相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
Chi Young Ok et al.
HAEMATOLOGICA (2019)
European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation
Nicole Engel et al.
LEUKEMIA (2019)
Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity
Peter van Galen et al.
CELL (2019)
Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia
Ross L. Levine et al.
HAEMATOLOGICA (2019)
Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse
Richard D. Press et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Evolutionary trajectory of leukemic clones and its clinical implications
Amos Tuval et al.
HAEMATOLOGICA (2019)
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
Adriano Venditti et al.
BLOOD (2019)
Clonal evolution of acute myeloid leukemia from diagnosis to relapse
Sebastian Vosberg et al.
GENES CHROMOSOMES & CANCER (2019)
Clonal hematopoiesis in human aging and disease
Siddhartha Jaiswal et al.
SCIENCE (2019)
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
Musa Yilmaz et al.
BLOOD CANCER JOURNAL (2019)
Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response
Hong Yuen Wong et al.
FRONTIERS IN ONCOLOGY (2019)
Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
Sanjay S. Patel et al.
BLOOD ADVANCES (2019)
Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML
Tracy Murphy et al.
BLOOD ADVANCES (2019)
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy
Guillermo Montalban-Bravo et al.
BLOOD ADVANCES (2019)
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia
V. I. Gaidzik et al.
LEUKEMIA (2018)
Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML
Yi Zhou et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group
Jason Aynardi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
Yann Ferret et al.
HAEMATOLOGICA (2018)
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
Kiyomi Morita et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
Maja Rothenberg-Thurley et al.
LEUKEMIA (2018)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia
Hidemasa Matsuo et al.
PEDIATRICS INTERNATIONAL (2018)
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
Yann Ferret et al.
HAEMATOLOGICA (2018)
Is it time to routinely incorporate MRD into practice?
Farhad Ravandi
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
Identifying patients with genetic predisposition to acute myeloid leukemia
Ellyn Obrochta et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
Felicitas Thol et al.
BLOOD (2018)
IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
Lucie Petrova et al.
CLINICAL BIOCHEMISTRY (2018)
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Uwe Platzbecker et al.
LANCET ONCOLOGY (2018)
Clinical consequences of clonal hematopoiesis of indeterminate potential
David P. Steensma
BLOOD ADVANCES (2018)
NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse
Alexander Hoellein et al.
BLOOD ADVANCES (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy
G. L. Uy et al.
LEUKEMIA (2017)
Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
Pierre Hirsch et al.
HAEMATOLOGICA (2017)
Improved OutcomesWith Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
Uwe Platzbecker et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML
S. Herold et al.
LEUKEMIA (2017)
Tracing the origins of relapse in acute myeloid leukaemia to stem cells
Liran I. Shlush et al.
NATURE (2017)
Measurement of Residual Disease in Acute Myeloid Leukemia
Rahul S. Vedula et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
Pierre Hirsch et al.
HAEMATOLOGICA (2017)
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation
Bartlomiej M. Getta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Clinical significance of somatic mutation in unexplained blood cytopenia
Luca Malcovati et al.
BLOOD (2017)
Mosaic chromosome 20q deletions are more frequent in the aging population
Mitchell J. Machiela et al.
BLOOD ADVANCES (2017)
Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML
Terrence N. Wong et al.
BLOOD (2016)
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial
Christophe Willekens et al.
HAEMATOLOGICA (2016)
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial
Christophe Willekens et al.
HAEMATOLOGICA (2016)
Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy
Katarzyna Rojek et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prognostic Significance of Mixed-Lineage Leukemia (MLL) Gene Detected by Real-Time Fluorescence Quantitative PCR Assay in Acute Myeloid Leukemia
Sai Huang et al.
MEDICAL SCIENCE MONITOR (2016)
The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia
Juan Ouyang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression
Catherine A. Cargo et al.
BLOOD (2015)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma et al.
BLOOD (2015)
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia
Jeffery M. Klco et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Mia Y. Platt et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone
C. N. Hahn et al.
LEUKEMIA (2015)
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the acute leukemia french association
Houria Debarri et al.
ONCOTARGET (2015)
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
R. Coleman Lindsley et al.
BLOOD (2015)
Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease
A. Kohlmann et al.
LEUKEMIA (2014)
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Liran I. Shlush et al.
NATURE (2014)
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Mingchao Xie et al.
NATURE MEDICINE (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome
Aref Al-Kali et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
Jan Kroenke et al.
BLOOD (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
John A. Liu Yin et al.
BLOOD (2012)
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
John S. Welch et al.
CELL (2012)
Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia
Hiroto Inaba et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype
Torsten Haferlach et al.
LEUKEMIA RESEARCH (2012)
RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant
Clara Ricci et al.
CLINICAL CANCER RESEARCH (2010)
Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning
F. Baron et al.
LEUKEMIA (2006)
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
P. Gorello et al.
LEUKEMIA (2006)
Nucleophosmin mutations in De novo acute myeloid leukemia:: The age-dependent incidences and the stability during disease
WC Chou et al.
CANCER RESEARCH (2006)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
